slides · global inventory
Present Solution
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 24,547
Current window 16,591-16,620
Pages 819
Rows per page 30
Slide function
16,591-16,620 of 24,547
21
The slide uses a hub-and-spoke diagram to illustrate the interconnected nature of the four advisory business lines.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Solution1 hit
26
The slide uses a circular diagram to categorize 'Solutions' and 'Applications' in capital markets.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Team1 hit
05
Lilium | Investor Presentation Deck | 16 slidesLilium | Investor Presentation Deck | 16 slides · Lilium
Conference presentation Investor relations Beat · Market Size1 hit
08
The slide introduces the core propulsion technology for the Lilium Jet.Lilium | Investor Presentation Deck | 16 slides · Lilium
Conference presentation Investor relations Beat · Product1 hit
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a visual comparison between telomere targeting (left) and PD-1/PD-L1 checkpoint inhibition (right).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
22
The slide shows a biological mechanism of action (MOA) validation using a dot plot to show TIFs increase over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to patient report generation.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide outlines a multi-step diagnostic process involving FIT analysis, automated extraction, qPCR, and AI/ML analysis.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
The slide uses a process flow to demonstrate the technical workflow of the diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
16
The slide outlines a multi-step diagnostic process involving FIT analysis and proprietary DNA/mRNA extraction.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
Uses a before-after-bridge style framing to contrast pain points with platform capabilities.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
The slide highlights the transition from RUO to cGMP capabilities across the product line.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide explicitly labels the model as 'Razor/Razor Blade Economics'.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
11
Uses the 'Razor/Razor Blade' business model framework.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Business Model1 hit
05
The slide uses a product photo to demonstrate the physical form factor of the sensor.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The screenshot shows a glucose trend line over time with a specific reading of 7.5 mmol/L.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
10
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
11
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
12
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
15
The slide uses a numbered list format to present two distinct product expansion paths.Nemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
17
Nemaura Medical | Investor Presentation Deck | 19 slidesNemaura Medical | Investor Presentation Deck | 19 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
07
The central diagram is a circular hub-and-spoke model representing the four pillars, surrounded by studio logos.Nexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations Beat · Business Model1 hit
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
08
Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide uses a list of icons to represent key clinical attributes of the drug candidate.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit